消栓肠溶胶囊联合阿替普酶治疗急性脑梗死临床效果

Analysisthe Clinical Effect of Xiaoshuan Changrong Capsule combined with Alteplase in the Treatment of Acute Cerebral Infarction

目的探讨急性脑梗死患者应用消栓肠溶胶囊联合阿替普酶治疗效果。方法选取2018年1月-2018年12月医院收治的78例急性脑梗死患者,按照入院先后顺序平均分为两组,各组39例,对照组实施阿替普酶治疗,观察组实施消栓肠溶胶囊联合阿替普酶治疗,统计各组治疗效果、治疗前后血清学指标、神经功能缺损评分(NIHSS)、运动能力评分(FMI)及日常生活能力(MBI)评分。结果在治疗总有效率方面,观察组92.31%(36/39),对照组71.79%(28/39),观察组较对照组更高,差异有统计学意义(P<0.05);在淀粉样蛋白(SAA)、神经生长因子(NGF)、血小板活化因子(PAF)、血清脂蛋白磷脂酶A2(Lp-PLA2)及胰岛素样生长因子-1(IGF-1)方面,治疗后,观察组均较对照组更优,差异有统计学意义(P<0.05);在MBI评分、FMI评分及NIHSS评分方面,治疗后,观察组较对照组更优,差异有统计学意义(P<0.05)。结论急性脑梗死疾病采取消栓肠溶胶囊联合阿替普酶治疗,不仅可以改善神经功能缺损病症,同时有助于血清学指标改善,值得推广。

Objective To investigate the therapeutic effect of Xiaoshuan Changrong capsule combined with alteplase in patients with acute cerebral infarction.Methods 78 patients with acute cerebral infarction admitted to our hospital from January2018 to December 2018 were divided into two groups according to the order of admission.39 patients in each group were treated with alteplase in the control group and alteplase in the research group.The therapeutic effect,serological indicators before and after treatment,neurological impairment score(NIHSS),motor ability score(FMI)and daily living ability score(MBI)were analyzed.Results The total effective rate was 92.31%in the research group and 71.79%in the control group.In terms of amyloid protein(SAA),nerve growth factor(NGF),platelet activation factor(PAF),serum lipoprotein phospholipase A2(lp-pla2)and insulin-like growth factor-1(igf-1),the study group was better than the control group after treatment,and the difference was statistically significant(P<0.05).In terms of MBI score,FMI score and NIHSS score,the study group was better than the control group after treatment,with statistically significant differences(P<0.05).Conclusion The treatment of acute cerebral infarction with xiaoshuan chang capsule combined with alteplase can not only improve the neurological defects,but also improve the serological indexes,which is worth popularizing and adopting.